Table 1.
Sociodemographic Characteristics
| Pooled Sample (N = 198) |
AIM Study (n = 162) |
ONS Study (n = 36) |
|||||
|---|---|---|---|---|---|---|---|
| Characteristic | M | (SD) | M | (SD) | M | (SD) | p |
| Age (years) | 59.1 | (7.5) | 60.6 | (6.1) | 52.4 | (9.5) | .0001 |
| Education (years) | 15.0 | (2.9) | 15.1 | (3.0) | 14.8 | (2.7) | .64 |
| Adherence | 88.7 | (1.6) | 87.2 | (24.6) | 95.4 | (8.9) | .21 |
| Depression (BDI total score) | 6.0 | (5.7) | 5.8 | (5.6) | 6.7 | (6.0) | .37 |
| Fatigue (POMS fatigue score) | 6.1 | (6.1) | 6.2 | (6.1) | 5.7 | (6.0) | .70 |
| Anxiety (POMS anxiety score) | 6.7 | (4.6) | 6.8 | (4.5) | 6.5 | (5.0) | .38 |
| n | (%) | n | (%) | n | (%) | ||
| Marital status | .80 | ||||||
| Never married | 20 | (10.1) | 18 | (11.1) | 2 | (5.6) | |
| Currently married | 136 | (68.7) | 109 | (67.3) | 27 | (75.0) | |
| Widowed | 16 | (8.1) | 13 | (8.0) | 3 | (8.3) | |
| Separated | 2 | (1.0) | 2 | (1.2) | 1 | (0.0) | |
| Divorced | 24 | (12.1) | 20 | (12.3) | 4 | (11.1) | |
| Employed | .55 | ||||||
| Yes | 138 | (69.7) | 111 | (68.5) | 27 | (75.0) | |
| No | 60 | (30.3) | 51 | (31.5) | 9 | (25.0) | |
| Ethnicity | .08 | ||||||
| White | 194 | (98.0) | 159 | (98.1) | 35 | (97.2) | |
| African American | 3 | (1.5) | 3 | (1.9) | 0 | (0.0) | |
| Multi-racial | 1 | (0.5) | 0 | (0.0) | 1 | (2.8) | |
| Latino | 2 | (1.0) | 1 | (0.6) | 1 | (2.8) | |
| Primary occupation | .06 | ||||||
| 1. Higher executivea | 50 | (26.2) | 40 | (20.9) | 10 | (5.2) | |
| 2. Administrativeb | 64 | (33.5) | 51 | (26.7) | 13 | (6.8) | |
| 3. Skilled/nonskilledc | 24 | (12.6) | 20 | (10.5) | 4 | (2.1) | |
| 4. Homemaker/otherd | 53 | (27.7) | 51 | (26.7) | 2 | (1.0) | |
| Menopausal status | .0001 | ||||||
| Premenopausal | 16 | (8.1) | 0 | (0.0) | 16 | (44.4) | |
| Postmenopausal | 182 | (91.9) | 162 | (100.0) | 20 | (55.6) | |
| MEMS-monitored medication | .0001 | ||||||
| Anastrozole | 69 | (85.4) | 62 | (100.0) | 7 | (19.4) | |
| Letrozole | 9 | (3.5) | 0 | (0.0) | 7 | (19.4) | |
| Examestane | 2 | (1.0) | 0 | (0.0) | 2 | (5.6) | |
| Tamoxifen | 19 | (9.6) | 0 | (0.0) | 19 | (52.8) | |
| Multiple AIs | 1 | (0.5) | 0 | (0.0) | 1 | (2.8) | |
| Radiation therapy | .03 | ||||||
| Radiation | 57 | (28.8) | 32 | (19.8) | 25 | (69.4) | |
| Mammosite | 12 | (6.1) | 12 | (7.4) | 0 | (0.0) | |
| Chemotherapy | .83 | ||||||
| Yes | 37 | (18.7) | 25 | (15.4) | 12 | (33.3) | |
| No | 60 | (30.3) | 39 | (24.1) | 21 | (58.3) | |
| Stage of breast cancer | .22 | ||||||
| LCIS | 1 | (0.5) | 1 | (0.6) | 0 | (0.0) | |
| I | 139 | (70.2) | 119 | (73.5) | 20 | (55.6) | |
| IIa | 35 | (17.7) | 26 | (16.0) | 9 | (25.0) | |
| IIb | 12 | (6.1) | 9 | (5.6) | 3 | (8.3) | |
| IIIa | 11 | (5.6) | 7 | (4.3) | 4 | (11.1) | |
| Tumor type | |||||||
| DCIS | 79 | (39.9) | 71 | (43.8) | 8 | (22.2) | .02 |
| LCIS | 7 | (3.5) | 5 | (3.1) | 2 | (5.6) | .61 |
| Infiltrating ductal | 170 | (85.9) | 142 | (87.7) | 28 | (77.8) | .18 |
| Tubular | 6 | (3.0) | 6 | (3.7) | 0 | (0.0) | .59 |
| Mucinous | 2 | (1.0) | 2 | (1.2) | 0 | (0.0) | 1.00 |
| Infiltrating lobular | 20 | (10.1) | 14 | (8.6) | 6 | (16.7) | .22 |
| Combination | 1 | (0.5) | 1 | (0.6) | 0 | (0.0) | 1.00 |
| Hormone replacement theory last 3 months | .36 | ||||||
| Yes | 23 | (11.6) | 20 | (12.3) | 3 | (8.3) | |
| No | 69 | (34.8) | 65 | (40.1) | 4 | (11.1) | |
Note. AI = aromatase inhibitors; BDI = Beck Depression Inventory; POMS = Profile of Mood States; DCIS = ductal carcinoma in situ. Women may have more than one type of breast cancer tumor. Participants with DCIS also had another tumor to be eligible for the parent studies.
a
Occupations included higher executive/medium-sized business, teacher, health care professional.
b
Occupations included clerical and sales.
c
Occupations included skilled-manual, nonskilled manual, and unskilled.
d
Occupations included homemaker, disabled, student, retired, and no occupation.